Using small molecule GSK3β inhibitors to treat inflammation

Current Medicinal Chemistry

Volumn 17, Issue 26, 2010, Pages 2873-2881

  Klamer, G ^a,b   Song, E ^b,c   Ko, K H ^c   O'Brien, T A ^b,c   Dolnikov, A ^b,c  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Glycogen synthase kinase 3 ; Gsk3 ; Immune system; Inflammation; T cells

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; TWS 119; UNCLASSIFIED DRUG; WNT PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STROKE;

ANTI-INFLAMMATORY AGENTS; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77955682056     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792065090     Document Type: Article

References (114)

1. Caligiuri, M.A. Human natural killer cells. Blood, 2008, 112, 461- 469.
2. Stow, J.L.; Ching Low, P.; Offenhauser, C.; Sangermani, D. Cytokine secretion in macrophages and other cells: pathways and mediators. Immunobiology, 2009, 214, 601-612.
3. Markey, K.A.; Banovic, T.; Kuns, R.D.; Olver, S.D.; Don, A.L.; Raffelt, N.C.; Wilson, Y.A.; Raggatt, L.J.; Pettit, A.R.; Bromberg, J.S.; Hill, G.R.; MacDonald, K.P. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood, 2009, 113, 5644-5649.
4. Hume, D.A. Macrophages as APC and the dendritic cell myth. J. Immunol., 2008, 181, 5829-5835.
5. Chtanova, T.; Schaeffer, M.; Han, S.J.; van Dooren, G.G.; Nollmann, M.; Herzmark, P.; Chan, S.W.; Satija, H.; Camfield, K.; Aaron, H.; Striepen, B.; Robey, E.A. Dynamics of neutrophil migration in lymph nodes during infection. Immunity, 2008, 29, 487-496.
6. Moser, M.; Murphy, K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol., 2000, 1, 199-205.
7. Eckl-Dorna, J.; Batista, F.D. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigenspecific plasma cell formation. Blood, 2009, 113, 3969-3977.
8. Bleackley, R.C. A molecular view of cytotoxic T lymphocyte induced killing. Biochem. Cell Biol., 2005, 83, 747-751.
9. Elenkov, I.J. Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci., 2004, 1024, 138-146.
10. Tsiligianni, I.; Antoniou, K.M.; Kyriakou, D.; Tzanakis, N.; Chrysofakis, G.; Siafakas, N.M.; Bouros, D. Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm. Med., 2005, 5, 8.
11. Constant, S.L.; Bottomly, K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol., 1997, 15, 297-322.
12. Luster, A.D. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol., 2002, 14, 129-135.
13. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol., 2003, 3, 133-146.
14. Hoebe, K.; Janssen, E.; Beutler, B. The interface between innate and adaptive immunity. Nat. Immunol., 2004, 5, 971-974.
15. Marks, D.J.; Segal, A.W. Innate immunity in inflammatory bowel disease: a disease hypothesis. J. Pathol., 2008, 214, 260-266.
16. Sartor, R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol., 2006, 3, 390-407.
17. Holmes, T.; O'Brien, T.A.; Knight, R.; Lindeman, R.; Symonds, G.; Dolnikov, A. The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis and leukaemia. Curr. Med. Chem., 2008, 15, 1493-1499.
18. Beurel, E.; Jope, R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol., 2006, 79, 173-189.
19. Cheng, Y.L.; Wang, C.Y.; Huang, W.C.; Tsai, C.C.; Chen, C.L.; Shen, C.F.; Chi, C.Y.; Lin, C.F. Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3betaregulated pathway. Infect. Immun., 2009, 77, 4002-4008.
20. Huang, W.C.; Lin, Y.S.; Wang, C.Y.; Tsai, C.C.; Tseng, H.C.; Chen, C.L.; Lu, P.J.; Chen, P.S.; Qian, L.; Hong, J.S.; Lin, C.F. Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology, 2009, 128, e275-286.
21. Yuskaitis, C.J.; Jope, R.S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal., 2009, 21, 264-273.
22. Rodionova, E.; Conzelmann, M.; Maraskovsky, E.; Hess, M.; Kirsch, M.; Giese, T.; Ho, A.D.; Zoller, M.; Dreger, P.; Luft, T. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood, 2007, 109, 1584-1592.
23. Jope, R.S.; Johnson, G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci., 2004, 29, 95-102.
24. Matsuda, T.; Zhai, P.; Maejima, Y.; Hong, C.; Gao, S.; Tian, B.; Goto, K.; Takagi, H.; Tamamori-Adachi, M.; Kitajima, S.; Sadoshima, J. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc. Natl. Acad. Sci. U.S.A, 2008, 105, 20900-20905.
25. Wei, W.; Jin, J.; Schlisio, S.; Harper, J.W.; Kaelin, W.G., Jr. The v- Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell, 2005, 8, 25-33.
26. Gregory, M.A.; Qi, Y.; Hann, S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem., 2003, 278, 51606-51612.
27. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov., 2004, 3, 479-487.
28. Mussmann, R.; Geese, M.; Harder, F.; Kegel, S.; Andag, U.; Lomow, A.; Burk, U.; Onichtchouk, D.; Dohrmann, C.; Austen, M. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J. Biol. Chem., 2007, 282, 12030-1207.
29. Martin, M.; Rehani, K.; Jope, R.S.; Michalek, S.M. Toll-like receptor- mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol., 2005, 6, 777-784.
30. Dugo, L.; Collin, M.; Allen, D.A.; Patel, N.S.; Bauer, I.; Mervaala, E.M.; Louhelainen, M.; Foster, S.J.; Yaqoob, M.M.; Thiemermann, C. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med., 2005, 33, 1903-1912.
31. Dugo, L.; Collin, M.; Allen, D.A.; Murch, O.; Foster, S.J.; Yaqoob, M.M.; Thiemermann, C. Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit. Care Med., 2006, 34, 1489-1496.
32. Cuzzocrea, S.; Mazzon, E.; Di Paola, R.; Muia, C.; Crisafulli, C.; Dugo, L.; Collin, M.; Britti, D.; Caputi, A.P.; Thiemermann, C. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin. Immunol., 2006, 120, 57-67.
33. Bao, Z.; Lim, S.; Liao, W.; Lin, Y.; Thiemermann, C.; Leung, B.P.; Wong, W.S. Glycogen synthase kinase-3beta inhibition attenuates asthma in mice. Am. J. Respir. Crit. Care Med., 2007, 176, 431-438.
34. Boufidou, F.; Nikolaou, C.; Alevizos, B.; Liappas, I.A.; Christodoulou, G.N. Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect. Disord., 2004, 82, 309-313.
35. Myint, A.M.; Leonard, B.E.; Steinbusch, H.W.; Kim, Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord., 2005, 88, 167-173.
36. Breunis, M.N.; Kupka, R.W.; Nolen, W.A.; Suppes, T.; Denicoff, K.D.; Leverich, G.S.; Post, R.M.; Drexhage, H.A. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry., 2003, 53, 157-165.
37. Hooper, C.; Killick, R.; Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem., 2008, 104, 1433-1439.
38. Block, M.L.; Hong, J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol., 2005, 76, 77-98.
39. Ring, D.B.; Johnson, K.W.; Henriksen, E.J.; Nuss, J.M.; Goff, D.; Kinnick, T.R.; Ma, S.T.; Reeder, J.W.; Samuels, I.; Slabiak, T.; Wagman, A.S.; Hammond, M.E.; Harrison, S.D. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes, 2003, 52, 588-595.
40. Notkins, A.L.; Lernmark, A. Autoimmune type 1 diabetes: resolved and unresolved issues. J. Clin. Invest., 2001, 108, 1247-1252.
41. Stukenbrock, H.; Mussmann, R.; Geese, M.; Ferandin, Y.; Lozach, O.; Lemcke, T.; Kegel, S.; Lomow, A.; Burk, U.; Dohrmann, C.; Meijer, L.; Austen, M.; Kunick, C. 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. J. Med. Chem., 2008, 51, 2196-2207.
42. Liu, Z.; Habener, J.F. Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia, 2009, 52, 1589-1598.
43. Tullai, J.W.; Chen, J.; Schaffer, M.E.; Kamenetsky, E.; Kasif, S.; Cooper, G.M. Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells. J. Biol. Chem., 2007, 282, 9482-9491.
44. Woodgett, J.R.; Ohashi, P.S. GSK3: an in-Toll-erant protein kinase? Nat. Immunol., 2005, 6, 51-752.
45. Du, Q.; Zhang, X.; Cardinal, J.; Cao, Z.; Guo, Z.; Shao, L.; Geller, D.A. Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res., 2009, 69, 3764-3771.
46. Duan, Y.; Liao, A.P.; Kuppireddi, S.; Ye, Z.; Ciancio, M.J.; Sun, J. beta-Catenin activity negatively regulates bacteria-induced inflammation. Lab. Invest., 2007, 87, 613-624.
47. Takada, Y.; Fang, X.; Jamaluddin, M.S.; Boyd, D.D.; Aggarwal, B.B. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem., 2004, 279, 39541-39554.
48. Deng, J.; Miller, S.A.; Wang, H.Y.; Xia, W.; Wen, Y.; Zhou, B.P.; Li, Y.; Lin, S.Y.; Hung, M.C. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell, 2002, 2, 323-334.
49. Schwabe, R.F.; Brenner, D.A. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 283, G204-211.
50. Ohtani, M.; Nagai, S.; Kondo, S.; Mizuno, S.; Nakamura, K.; Tanabe, M.; Takeuchi, T.; Matsuda, S.; Koyasu, S. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood, 2008, 112, 635-643.
51. Gattinoni, L.; Klebanoff, C.A.; Restifo, N.P. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Sci. Transl. Med., 2009, 1, 11ps12.
52. Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci., 2004, 25, 471-480.
53. Sun, K.; Welniak, L.A.; Panoskaltsis-Mortari, A.; O'Shaughnessy, J.; Liu, H.; Barao, I.; Riordan, W.; Sitcheran, R.; Wysocki, C.; Serody, J.S.; Blazar, B.R.; Sayers, T.J.; Murphy, W.J. Inhibition of acute graft. Acad. Sci. U.S.A., 2004, 101, 120-125.
54. MacDonald, K.P.; Kuns, R.D.; Rowe, V.; Morris, E.S.; Banovic, T.; Bofinger, H.; O'Sullivan, B.; Markey, K.A.; Don, A.L.; Thomas, R.; Hill, G.R. Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. Blood, 2007, 109, 5049-5057.
55. Vodanovic-Jankovic, S.; Hari, P.; Jacobs, P.; Komorowski, R.; Drobyski, W.R. NF-kappaB as a target for the prevention of graftversus-host disease: comparative efficacy of bortezomib and PS-1145. Blood, 2006, 107, 827-834.
56. Pahan, K.; Schmid, M. Activation of nuclear factor-kB in the spinalcord of experimental allergic encephalomyelitis. Neurosci. Lett., 2000, 287, 17-20.
57. Campo, G.M.; Avenoso, A.; Campo, S.; D'Ascola, A.; Traina, P.; Calatroni, A. Chondroitin-4-sulphate inhibits NF-kB translocation and caspase activation in collagen-induced arthritis in mice. Osteoarthritis Cartilage, 2008, 16, 1474-1483.
58. Han, Z.; Boyle, D.L.; Manning, A.M.; Firestein, G.S. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collageninduced arthritis. Autoimmunity, 1998, 28, 197-208.
59. Starkey, J.M.; Haidacher, S.J.; LeJeune, W.S.; Zhang, X.; Tieu, B.C.; Choudhary, S.; Brasier, A.R.; Denner, L.A.; Tilton, R.G. Diabetes-induced activation of canonical and noncanonical nuclear factor-kappaB pathways in renal cortex. Diabetes, 2006, 55, 1252-1259.
60. Gagliardo, R.; Chanez, P.; Mathieu, M.; Bruno, A.; Costanzo, G.; Gougat, C.; Vachier, I.; Bousquet, J.; Bonsignore, G.; Vignola, A.M. Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am. J. Respir. Crit. Care Med., 2003, 168, 1190-1198.
61. Gan, H.T.; Chen, Y.Q.; Ouyang, Q. Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. J. Gastroenterol. Hepatol., 2005, 20, 1016-1024.
62. Yan, J.; Greer, J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets, 2008, 7, 536-557.
63. Lizzul, P.F.; Aphale, A.; Malaviya, R.; Sun, Y.; Masud, S.; Dombrovskiy, V.; Gottlieb, A.B. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J. Invest. Dermatol., 2005, 124, 1275-1283.
64. Wei, J.F.; Zheng, S.S. NF-kappa B in allograft rejection. Hepatobiliary Pancreat. Dis. Int., 2003, 2, 180-183.
65. Savinova, O.V.; Hoffmann, A.; Ghosh, G. The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecularweight heterogeneous complexes. Mol. Cell, 2009, 34, 591-602.
66. Braat, H.; Rottiers, P.; Hommes, D.W.; Huyghebaert, N.; Remaut, E.; Remon, J.P.; van Deventer, S.J.; Neirynck, S.; Peppelenbosch, M.P.; Steidler, L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol., 2006, 4, 754-759.
67. Basak, S.; Kim, H.; Kearns, J.D.; Tergaonkar, V.; O'Dea, E.; Werner, S.L.; Benedict, C.A.; Ware, C.F.; Ghosh, G.; Verma, I.M.; Hoffmann, A. A fourth IkappaB protein within the NF-kappaB signaling module. Cell, 2007, 128, 369-381.
68. Tergaonkar, V.; Correa, R.G.; Ikawa, M.; Verma, I.M. Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity. Nat. Cell Biol., 2005, 7, 921-923.
69. Zha, J.; Han, K.J.; Xu, L.G.; He, W.; Zhou, Q.; Chen, D.; Zhai, Z.; Shu, H.B. The Ret finger protein inhibits signaling mediated by the noncanonical and canonical IkappaB kinase family members. J. Immunol., 2006, 176, 1072-1080.
70. Frelin, C.; Imbert, V.; Griessinger, E.; Peyron, A.C.; Rochet, N.; Philip, P.; Dageville, C.; Sirvent, A.; Hummelsberger, M.; Berard, E.; Dreano, M.; Sirvent, N.; Peyron, J.F. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood, 2005, 105, 804-811.
71. Steinbrecher, K.A.; Wilson, W., 3rd; Cogswell, P.C.; Baldwin, A.S. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol. Cell Biol., 2005, 25, 8444-8455.
72. Hoeflich, K.P.; Luo, J.; Rubie, E.A.; Tsao, M.S.; Jin, O.; Woodgett, J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature, 2000, 406, 86-90.
73. Ougolkov, A.V.; Bone, N.D.; Fernandez-Zapico, M.E.; Kay, N.E.; Billadeau, D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood, 2007, 110, 735-742.
74. Wilson, W., 3rd; Baldwin, A.S. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res., 2008, 68, 8156-8163.
75. Bournat, J.C.; Brown, A.M.; Soler, A.P. Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells. J. Neurosci. Res., 2000, 61, 21-32.
76. Demarchi, F.; Bertoli, C.; Sandy, P.; Schneider, C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J. Biol. Chem., 2003, 278, 39583-39590.
77. Sanchez, J.F.; Sniderhan, L.F.; Williamson, A.L.; Fan, S.; Chakraborty- Sett, S.; Maggirwar, S.B. Glycogen synthase kinase 3betamediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol. Cell Biol., 2003, 23, 4649-4662.
78. Kim, C.; Wilcox-Adelman, S.; Sano, Y.; Tang, W.J.; Collier, R.J.; Park, J.M. Antiinflammatory cAMP signaling and cell migration genes co-opted by the anthrax bacillus. Proc. Natl. Acad. Sci. U.S.A, 2008, 105, 6150-6155.
79. Liopeta, K.; Boubali, S.; Virgilio, L.; Thyphronitis, G.; Mavrothalassitis,G.; Dimitracopoulos, G.; Paliogianni, F. cAMP regulates IL-10 production by normal human T lymphocytes at multiple levels: a potential role for MEF2. Mol. Immunol., 2009, 46, 345-354.
80. Gee, K.; Angel, J.B.; Mishra, S.; Blahoianu, M.A.; Kumar, A. IL- 10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/calmodulin-dependent protein kinaseactivated p38 MAPK and Sp-1 and CREB-1 transcription factors. J. Immunol., 2007, 178, 798-807.
81. Gotschel, F.; Kern, C.; Lang, S.; Sparna, T.; Markmann, C.; Schwager, J.; McNelly, S.; von Weizsacker, F.; Laufer, S.; Hecht, A.; Merfort, I. Inhibition of GSK3 differentially modulates NFkappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. Exp. Cell Res., 2008, 314, 1351-1366.
82. Liang, M.H.; Wendland, J.R.; Chuang, D.M. Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol. Cell Neurosci., 2008, 37, 440-453.
83. Fiol, C.J.; Williams, J.S.; Chou, C.H.; Wang, Q.M.; Roach, P.J.; Andrisani, O.M. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem., 1994, 269, 32187-32193.
84. Brockman, M.A.; Kwon, D.S.; Tighe, D.P.; Pavlik, D.F.; Rosato, P.C.; Sela, J.; Porichis, F.; Le Gall, S.; Waring, M.T.; Moss, K.; Jessen, H.; Pereyra, F.; Kavanagh, D.G.; Walker, B.D.; Kaufmann, D.E. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood, 2009, 114, 346-356.
85. Hashimoto, S.I.; Komuro, I.; Yamada, M.; Akagawa, K.S. IL-10 inhibits granulocyte-macrophage colony-stimulating factordependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. J. Immunol., 2001, 167, 3619-3625.
86. Grimbaldeston, M.A.; Nakae, S.; Kalesnikoff, J.; Tsai, M.; Galli, S.J. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol., 2007, 8, 1095-1104.
87. Nishimura, M.; Sato, H.; Okazaki, H.; Satake, M.; Tadokoro, K. Interleukin-10 containing normal human serum inhibits granzyme B release but not perforin release from alloreactive and EBVspecific T cell clones. Cell. Immunol., 2008, 251, 31-36.
88. Strle, K.; McCusker, R.H.; Johnson, R.W.; Zunich, S.M.; Dantzer, R.; Kelley, K.W. Prototypical anti-inflammatory cytokine IL-10 prevents loss of IGF-I-induced myogenin protein expression caused by IL-1beta. Am. J. Physiol. Endocrinol. Metab., 2008, 294, E709- 718.
89. Bhattacharyya, S.; Sen, P.; Wallet, M.; Long, B.; Baldwin, A.S., Jr.; Tisch, R. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood, 2004, 104, 1100-1109.
90. Dhingra, S.; Sharma, A.K.; Arora, R.C.; Slezak, J.; Singal, P.K. IL- 10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. Cardiovasc. Res., 2009, 82, 59-66.
91. Tolar, J.; Hippen, K.L.; Blazar, B.R. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br. J. Haematol., 2009, 147, 200-206.
92. Fu, C.L.; Chuang, Y.H.; Huang, H.Y.; Chiang, B.L. Induction of IL-10 producing CD4+ T cells with regulatory activities by stimulation with IL-10 gene-modified bone marrow derived dendritic cells. Clin. Exp. Immunol., 2008, 153, 258-268.
93. Chen, Z.M.; O'Shaughnessy, M.J.; Gramaglia, I.; Panoskaltsis- Mortari, A.; Murphy, W.J.; Narula, S.; Roncarolo, M.G.; Blazar, B.R. IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood, 2003, 101, 5076-5083.
94. Mu, W.; Ouyang, X.; Agarwal, A.; Zhang, L.; Long, D.A.; Cruz, P.E.; Roncal, C.A.; Glushakova, O.Y.; Chiodo, V.A.; Atkinson, M.A.; Hauswirth, W.W.; Flotte, T.R.; Rodriguez-Iturbe, B.; Johnson, R.J. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J. Am. Soc. Nephrol., 2005, 16, 3651-3660.
95. Holmes, T.; O'Brien, T.A.; Knight, R.; Lindeman, R.; Shen, S.; Song, E.; Symonds, G.; Dolnikov, A. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells, 2008, 26, 1288-1297.
96. Staal, F.J.; Burgering, B.M.; van de Wetering, M.; Clevers, H.C. Tcf-1-mediated transcription in T lymphocytes: differential role for glycogen synthase kinase-3 in fibroblasts and T cells. Int. Immunol., 1999, 11, 317-323.
97. Wang, X.; Adhikari, N.; Li, Q.; Guan, Z.; Hall, J.L. The role of beta-transducin repeat-containing protein (beta-TrCP) in the regulation of NF-kappaB in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 85-90.
98. Diks, S.H.; Hardwick, J.C.; Diab, R.M.; van Santen, M.M.; Versteeg, H.H.; van Deventer, S.J.; Richel, D.J.; Peppelenbosch, M.P. Activation of the canonical beta-catenin pathway by histamine. J. Biol. Chem., 2003, 278, 52491-52496.
99. Ding, Y.; Shen, S.; Lino, A.C.; Curotto de Lafaille, M.A.; Lafaille, J.J. Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat. Med., 2008, 14, 162-169.
100. Crist, S.A.; Sprague, D.L.; Ratliff, T.L. Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes. Blood, 2008, 111, 3553-3561.
101. Drenning, J.A.; Lira, V.A.; Simmons, C.G.; Soltow, Q.A.; Sellman, J.E.; Criswell, D.S. Nitric oxide facilitates NFAT-dependent transcription in mouse myotubes. Am. J. Physiol. Cel. Physiol., 2008, 294, C1088-1095.
102. Holowachuk, E.W. Nuclear factor of activated T cell (NFAT) transcription proteins regulate genes involved in adipocyte metabolism and lipolysis. Biochem. Biophys. Res. Commun., 2007, 361, 427-432.
103. Fiedler, B.; Wollert, K.C. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc. Res., 2004, 63, 450-457.
104. Murphy, L.L.; Hughes, C.C. Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: involvement of the wnt/glycogen synthase kinase-3 beta pathway. J. Immunol., 2002, 169, 3717-3725.
105. Ohteki, T.; Parsons, M.; Zakarian, A.; Jones, R.G.; Nguyen, L.T.; Woodgett, J.R.; Ohashi, P.S. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J. Exp. Med., 2000, 192, 99-104.
106. Doble, B.W.; Woodgett, J.R. GSK-3: tricks of the trade for a multitasking kinase. J. Cell Sci., 2003, 116, 1175-1186.
107. Meijer, L.; Skaltsounis, A.L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X.P.; Vonica, C.A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S.M.; Pearl, L.; Greengard, P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol., 2003, 10, 1255-1266.
108. Jope, R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci., 2003, 24, 441-443.
109. Castro, A.; Encinas, A.; Gil, C.; Brase, S.; Porcal, W.; Perez, C.; Moreno, F.J.; Martinez, A. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. Bioorg. Med. Chem., 2008, 16, 495-510.
110. Martinez, A.; Alonso, M.; Castro, A.; Perez, C.; Moreno, F.J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 2002, 45, 1292-1299.
111. Coghlan, M.P.; Culbert, A.A.; Cross, D.A.; Corcoran, S.L.; Yates, J.W.; Pearce, N.J.; Rausch, O.L.; Murphy, G.J.; Carter, P.S.; Roxbee Cox, L.; Mills, D.; Brown, M.J.; Haigh, D.; Ward, R.W.; Smith, D.G.; Murray, K.J.; Reith, A.D.; Holder, J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol., 2000, 7, 793-803.
112. Phukan, S.; Babu, V.; Kannoji, A.; Hariharan, R.; Balaji, V. GSK3beta: role in therapeutic landscape and development of modulators. Br. J. Pharmacol., 2010, 160, 1-19.
113. Frame, S.; Cohen, P.; Biondi, R.M. A Common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell, 2001, 7, 1321-1327.
114. Martinez, A.; Perez, D.I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J. Alz. Dis., 2008, 15, 181-91.